Center for Vaccine Development and Global Health, University of Maryland, Baltimore, MA, USA.
Department of Medical Statistics, Faculty of Epidemiology and Population Health, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Lancet Glob Health. 2020 Dec;8(12):e1499-e1511. doi: 10.1016/S2214-109X(20)30325-9. Epub 2020 Oct 22.
The burden of malaria infection in sub-Saharan Africa among school-aged children aged 5-15 years is underappreciated and represents an important source of human-to-mosquito transmission of Plasmodium falciparum. Additional interventions are needed to control and eliminate malaria. We aimed to assess whether preventive treatment of malaria might be an effective means of reducing P falciparum infection and anaemia in school-aged children and lowering parasite transmission.
In this systematic review and two meta-analyses, we searched the online databases PubMed, Embase, Cochrane CENTRAL, and Clinicaltrials.gov for intervention studies published between Jan 1, 1990, and Dec 14, 2018. We included randomised studies that assessed the effect of antimalarial treatment among asymptomatic school-aged children aged 5-15 years in sub-Saharan Africa on prevalence of P falciparum infection and anaemia, clinical malaria, and cognitive function. We first extracted data for a study-level meta-analysis, then contacted research groups to request data for an individual participant data meta-analysis. Outcomes of interest included prevalence of P falciparum infection detected by microscopy, anaemia (study defined values or haemoglobin less than age-adjusted and sex-adjusted values), clinical malaria (infection and symptoms on the basis of study-specific definitions) during follow-up, and code transmission test scores. We assessed effects by treatment type and duration of time protected, and explored effect modification by transmission setting. For study-level meta-analysis, we calculated risk ratios for binary outcomes and standardised mean differences for continuous outcomes and pooled outcomes using fixed-effect and random-effects models. We used a hierarchical generalised linear model for meta-analysis of individual participant data. This study is registered with PROSPERO, CRD42016030197.
Of 628 studies identified, 13 were eligible for the study-level meta-analysis (n=16 309). Researchers from 11 studies contributed data on at least one outcome (n=15 658) for an individual participant data meta-analysis. Interventions and study designs were highly heterogeneous; overall risk of bias was low. In the study-level meta-analysis, treatment was associated with reductions in P falciparum prevalence (risk ratio [RR] 0·27, 95% CI 0·17-0·44), anaemia (0·77, 0·65-0·91), and clinical malaria (0·40, 0·28-0·56); results for cognitive outcomes are not presented because data were only available for three trials. In our individual participant data meta-analysis, we found treatment significantly decreased P falciparum prevalence (adjusted RR [ARR] 0·46, 95% CI 0·40-0·53; p<0·0001; 15 648 individuals; 11 studies), anaemia (ARR 0·85, 0·77-0·92; p<0·0001; 15 026 individuals; 11 studies), and subsequent clinical malaria (ARR 0·50, 0·39-0·60; p<0·0001; 1815 individuals; four studies) across transmission settings. We detected a marginal effect on cognitive function in children older than 10 years (adjusted mean difference in standardised test scores 0·36, 0·01-0·71; p=0·044; 3962 individuals; five studies) although we found no significant effect when combined across all ages.
Preventive treatment of malaria among school-aged children significantly decreases P falciparum prevalence, anaemia, and risk of subsequent clinical malaria across transmission settings. Policy makers and programme managers should consider preventive treatment of malaria to protect this age group and advance the goal of malaria elimination, while weighing these benefits against potential risks of chemoprevention.
US National Institutes of Health and Burroughs Wellcome Fund/ASTMH Fellowship.
在撒哈拉以南非洲地区,5-15 岁学龄儿童的疟疾感染负担被低估,这是恶性疟原虫向蚊子传播的重要来源。需要采取额外的干预措施来控制和消除疟疾。我们旨在评估疟疾的预防治疗是否可能是减少学龄儿童中恶性疟原虫感染和贫血以及降低寄生虫传播的有效手段。
在这项系统评价和两项荟萃分析中,我们在 1990 年 1 月 1 日至 2018 年 12 月 14 日期间,在 PubMed、Embase、Cochrane CENTRAL 和 ClinicalTrials.gov 在线数据库中搜索了干预研究。我们纳入了评估在撒哈拉以南非洲地区 5-15 岁无症状学龄儿童中使用抗疟药物治疗对恶性疟原虫感染和贫血、临床疟疾和认知功能的影响的随机研究。我们首先为研究水平的荟萃分析提取数据,然后联系研究小组,要求提供个体参与者数据荟萃分析的数据。感兴趣的结局包括通过显微镜检测到的恶性疟原虫感染的流行率、贫血(研究定义的数值或血红蛋白低于年龄和性别调整的值)、随访期间的临床疟疾(根据研究特定定义的感染和症状)和传播测试评分。我们按治疗类型和保护时间的长短评估效果,并探索传播环境的效果修饰。对于研究水平的荟萃分析,我们使用固定效应和随机效应模型计算二项结局的风险比和连续结局的标准化均数差,并使用分层广义线性模型进行个体参与者数据的荟萃分析。这项研究在 PROSPERO 上注册,注册号为 CRD42016030197。
在 628 项研究中,有 13 项符合研究水平的荟萃分析(n=16309)。11 项研究的研究人员提供了至少一项结局(n=15658)的个体参与者数据荟萃分析数据。干预措施和研究设计高度异质;整体偏倚风险较低。在研究水平的荟萃分析中,治疗与恶性疟原虫流行率降低相关(风险比[RR]0·27,95%CI 0·17-0·44)、贫血(0·77,0·65-0·91)和临床疟疾(0·40,0·28-0·56);由于只有三项试验提供了数据,因此没有报告认知结局的结果。在我们的个体参与者数据荟萃分析中,我们发现治疗显著降低了恶性疟原虫流行率(调整后的 RR [ARR]0·46,95%CI 0·40-0·53;p<0·0001;15648 人;11 项研究)、贫血(ARR 0·85,0·77-0·92;p<0·0001;15026 人;11 项研究)和随后的临床疟疾(ARR 0·50,0·39-0·60;p<0·0001;1815 人;四项研究)在不同的传播环境中。我们在年龄大于 10 岁的儿童中检测到认知功能的边缘效应(标准化测试分数的调整平均差异 0·36,0·01-0·71;p=0·044;3962 人;五项研究),但当综合所有年龄时,我们没有发现显著的效果。
在撒哈拉以南非洲地区,5-15 岁学龄儿童的疟疾预防治疗显著降低了恶性疟原虫的流行率、贫血和随后的临床疟疾风险,无论在何种传播环境下均有效果。政策制定者和项目管理者应考虑对疟疾进行预防治疗,以保护这一年龄组并推进消除疟疾的目标,同时权衡这些益处与化学预防的潜在风险。
美国国立卫生研究院和 Burroughs Wellcome 基金/ASTMH 奖学金。